[Detection of fecal peroxisome proliferator-activated receptor delta and cyclooxygenase 2 mRNA in screening of colorectal cancer].
To evaluate the detection of fecal PPAR-delta and COX-2 mRNA in screening of colorectal cancer. Fifty-one patients with colorectal cancer and 21 healthy controls were included in this study. Total RNA was isolated from the fecal samples. Expression of PPAR-delta and COX-2 mRNA was determined by RT-PCR, and its value in screening of colorectal cancer was investigated. The positive detection rate of fecal PPAR-delta and COX-2 mRNA in colorectal cancer patients was significantly higher than that in healthy controls. In 47 colorectal cancer patients and 19 healthy controls with positive fecal ACTB mRNA expression, the sensitivity of fecal PPAR-delta mRNA, COX-2 mRNA and PPAR-delta mRNA plus COX-2 mRNA detection in diagnosing colorectal cancer was 76.6%(36/47), 80.9%(38/47) and 91.5%(43/47) respectively; the specificity was 63.2%(12/19), 84.2%(16/19) and 89.5%(17/19) respectively. The combination detection of fecal PPAR-delta and COX-2 mRNA is effective in screening human colorectal cancer and is better than detection of single marker alone.